Disease · MONDO_0015129

chronic primary adrenal insufficiency

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. chronic primary adrenal insufficiency. Diseases, record MONDO_0015129. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015129

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: chronic primary adrenal insufficiency; Open Targets
Open Targets ID: MONDO_0015129; Open Targets
Other names: Addison disease, CPAI, chronic adrenocorticoid insufficiency, hypoadrenocorticism, familial, primary adrenal insufficiency, chronic, primary hypoadrenalism; Open Targets
Disease Ontology: DOID:13774; Disease Ontology
MeSH: D000224; MeSH
NCI Thesaurus: C26689; NCI Thesaurus
Orphanet: ORPHA:101959; Orphanet
Highest stage of its drugs: Approval, for 2 of its 3 drugs, from DailyMed and TTD; Open Targets

Drugs3

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DESOXYCORTICOSTERONE PIVALATE	CHEMBL1200592	Small molecule	Approval	TTD	1	0	0	Drugs and targets
FLUDROCORTISONE ACETATE	CHEMBL1201010	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
HYDROCORTISONE	CHEMBL389621	Small molecule	Phase 2/3	ClinicalTrials.gov	5	5	5	Drugs and targets

Targets2

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C2	Mineralocorticoid receptor	2	Mineralocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/4306	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 2/3	https://conductscience.org/library/genes/2908	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00915343	Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency	Phase 2/3	64	2015-07-20	Adrenal Insufficiency	HYDROCORTISONE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01063569	Glucocorticoid Treatment in Addison's Disease	Phase 2/3	33		Addison's Disease	HYDROCORTISONE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01847690	Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure	Phase 2	20		Addison Disease	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT02096510	Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia	Phase 1/2	8		Addison Disease, Adrenal Hyperplasia Congenital	HYDROCORTISONE	Its record names the disease	ClinicalTrials.gov
NCT05716607	Treatment Study in Patients Treated With Both Insulin & Hydrocortisone	Not applicable	0		Diabetes Mellitus, Adrenal Insufficiency, Polyglandular Autoimmune Syndrome	HYDROCORTISONE	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37172949	RESULT	1	PubMed
33236103	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015129

GET https://conductscience.org/api/diseases/v1/MONDO_0015129/drugs

API reference For AI assistants